Ratio Therapeutics Inc.
PrivateLast Round
Series C
Jul 31, 2026
Total Funding Raised
$90M
Momentum
Top 5%
of companies Caplight tracks
Company Overview
Ratio Therapeutics Inc. is a biotechnology company that develops next-generation precision radiopharmaceuticals for the treatment of solid tumors.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Ratio Therapeutics Inc. Comparables
Compare Ratio Therapeutics Inc. with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| ARTBIO | 92% | |
| Aktis Oncology | 89% | |
| Actithera | 87% |
Ratio Therapeutics Inc. Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series C | Jul 31, 2026 | ||||
| Series B | Jan 17, 2024 | ||||
| Series A | Feb 1, 2023 | ||||
| Seed | Jun 10, 2022 |
Ratio Therapeutics Inc. Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Center for Technology Licensing at Cornell University | Series B |
| Duquesne Family Office | Series C, Series A |
| Pags Group | Series B |
| Charles and Lynn Schusterman Family Philanthropies | Series A |
| Schusterman Family Investments | Series A, Series B |
| Catalio Capital Management | Series A, Series C |
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 21, 2026
Monthly visitors increased 55% MoM, reaching 6.1K.
- Jul 31, 2026
$70M round with participation from Catalio Capital Management and Duquesne Family Office.
Recent news
Latest coverage and updates
- partners_withSep 9, 2026
Ratio Therapeutics partnered with RayzeBio, Inc. on Sep 9th '26.
- receives_financingAug 3, 2026
Ratio Therapeutics received financing of $70M in Series C on Aug 3rd '26.
- is_developingJun 19, 2026
Ratiotx is developing radiopharmaceuticals for solid tumors on Jun 19th '26.
Ratio Therapeutics Inc. Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Ratio Therapeutics Inc.'s valuation, stock price, and market status.
Is RatioTX a public or private company?
RatioTX is a private company.
What is the current stock price of RatioTX?
RatioTX is a private company with no public stock price. No recent secondary market data is available.
How much is RatioTX worth (valuation)?
Valuation information for RatioTX is not publicly available.
Can I buy RatioTX stock?
RatioTX shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was RatioTX's last funding round?
RatioTX's most recent funding round was Series B on January 17, 2024.
Who are the main investors in RatioTX?
Key investors in RatioTX include Duquesne Family Office, Charles and Lynn Schusterman Family Philanthropies, Schusterman Family Investments.
Will RatioTX IPO soon?
No public IPO plans have been announced for RatioTX.
How can I track RatioTX secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor RatioTX's secondary market activity and sign up for updates.